To Evaluate Current Efficacy of Antimalarials Used in Timika, Papua, Indonesia
Falciparum Malaria, Vivax Malaria
About this trial
This is an interventional treatment trial for Falciparum Malaria focused on measuring Falciparum, Vivax, Papua, Chloroquine, Sulphadoxine-pyrimethamine
Eligibility Criteria
Inclusion Criteria: -Male and female patients at least one 1year of age and weighing more than 10kg. -Microscopic confirmation of P. falciparum and /or P.vivax infection (any parasitaemia). -Fever (axillary temperature >37.5oC) or history of fever in the last 48 hours. -Able to participate in the trial and comply with the clinical trial protocol -Written informed consent to participate in trial; verbal consent in presence of literate witness is required for illiterate patients, and written consent from parents/guardian for children below age of consent Exclusion Criteria: Pregnancy or lactation -Inability to tolerate oral treatment -Signs/symptoms indicative of severe/complicated malaria or warning signs requiring parenteral treatment -Known hypersensitivity or allergy to artemisinin derivatives -Serious underlying disease (cardiac, renal or hepatic) -Parasitaemia >4%
Sites / Locations
- SP9 & SP12 Public Health- Malaria control clinics